A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

We explored in a phase I/II clinical trial the combination of valproic acid (VPA), a clinically available histone deacetylase inhibitor, with standard chemoimmunotherapy in patients with advanced melanoma, to evaluate its clinical activity, to correlate the clinical response with the biological acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocca, A, Minucci, S, Tosti, G, Croci, D, Contegno, F, Ballarini, M, Nolè, F, Munzone, E, Salmaggi, A, Goldhirsch, A, Pelicci, P G, Testori, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634690/
https://www.ncbi.nlm.nih.gov/pubmed/19127265
http://dx.doi.org/10.1038/sj.bjc.6604817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634690/
https://www.ncbi.nlm.nih.gov/pubmed/19127265
http://dx.doi.org/10.1038/sj.bjc.6604817

Ejemplares similares